首页> 外文会议>International Seminar on Smart Molecule of Natural Resources >The Improvement of INS Gene Sequences on Rat Model of Type 1 Diabetes in Goat Milk Casein Protein Treatment, but not in Glibenclamide
【24h】

The Improvement of INS Gene Sequences on Rat Model of Type 1 Diabetes in Goat Milk Casein Protein Treatment, but not in Glibenclamide

机译:山羊乳酪蛋白治疗1型糖尿病大鼠基因序列的改善,但在Glibenclamide中

获取原文

摘要

This study was aimed to determine the effect of CSN1S2 protein from Etawah Crossbred goat milk for repairing DNA sequence of INS gene in T1DM rat model. We divided the experimental rats into control group, diabetes group, control with CSN1S2 protein treatment group, diabetes with CSN1S2 protein treatment group, and diabetes with glibenclamide treatment group. The dose of CSN1S2 protein and glibenclamide used was 800 mg/kg BW and 5 mg/kg BW, respectively. We isolated the DNA from rat pancreas tissue and amplified it with a specific primer of INS gene. Our study investigated that there were transition, transversion, and deletion mutation in diabetic rat. The glibenclamide administration had changed 6 point mutations in INS of the diabetic rat to normal, but it created the other 9 new mutations. The CSN1S2 protein treatment showed mutation repairing in INS of diabetes group. Consequently, CSN1S2 have potential effect as anti-diabetes and is safe to consume than glibenclamide.
机译:该研究旨在确定CSN1S2蛋白来自Etawah杂交山羊牛奶的影响,用于修复T1DM大鼠模型中的INS基因DNA序列。 我们将实验大鼠分为对照组,糖尿病组,用CSN1S2蛋白处理组对照,糖尿病用CSN1S2蛋白处理组,以及Glibenclamide治疗组的糖尿病。 使用的CSN1S2蛋白和Glibenclamide的剂量分别为800mg / kg Bw和5mg / kg bw。 我们将DNA与大鼠胰腺组织分离并用INS基因的特异性引物扩增。 我们的研究调查了糖尿病大鼠中存在过渡,转化和缺失突变。 Glibenclamide施用在糖尿病大鼠中改变了6点突变到正常,但它产生了其他9个新突变。 CSN1S2蛋白处理显示糖尿病组INS的突变修复。 因此,CSN1S2具有潜在的效果作为抗糖尿病,并且可以比Glibenclamide安全地消耗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号